We are seeking an enthusiastic and dedicated Clinical Trial Coordinator to join the Prostate Cancer Targeted Therapy Group. This team conducts industry-sponsored early-phase clinical trials of novel anticancer therapies. As part of a world-class clinical trials unit, based within the Royal Marsden Hospital, we are committed to advancing cancer treatment through the development of innovative therapeutics that aim to improve patient care.
About you
The successful candidate will hold a degree in life sciences or nursing and have a minimum of two years’ experience in clinical trials, with a solid understanding of the conduct of oncology trials across Phases I–IV. The role requires the ability to manage operational activities across multiple complex clinical trials simultaneously and to serve as a key point of communication within the study team and with external partners, ensuring trials are delivered in accordance with protocol and ICH-GCP standards.
Applicants must be highly organised, capable of planning work effectively within a busy clinical and ward environment and possess excellent communication and interpersonal skills to engage confidently with staff and patients.
Department/Directorate Information
The Prostate Cancer Targeted Therapy Group (PCTTG) is one of the most recognized groups and a world leader in running prostate cancer clinical trials. It specialises in developing new therapies to improve treatment for advanced prostate cancer patients; with a specific interest in biomarker-driven clinical trials.
Since its opening in 2004, the PCTTG, led by Professor Johann de Bono, has driven innovative design and conduct of biomarker-led, hypothesis-testing clinical trials supported by highly informative laboratory studies, and has had a huge scientific and clinical impact. The team, alongside its partners and collaborators, has made critical contributions to elucidating the biology and clinical understanding of prostate cancer, and to transforming translational research and outcomes for this commonest of male malignancies. It has facilitated the development of many novel anti-cancer drugs which are now approved treatments for men with advanced prostate cancer, including abiraterone, enzalutamide, cabazitaxel, and olaparib.
The PCTTG led and conducted clinical trials that demonstrated the efficacy and safety of abiraterone, resulting in the drug's regulatory approval around the world. Abiraterone has been administered to more than 400,000 men worldwide, with evidence indicating that it can improve life expectancy by at least a year while significantly improving quality of life. In addition, the PCTTG played a role in the successful development of enzalutamide and cabazitaxel, resulting in the drugs’ registration, which now form standard-of-care therapies for lethal prostate cancer. Finally, the PCTTG’s work on olaparib in DNA repair-defective prostate cancers, utilizing a novel investigator-initiated adaptive trial design, provided impetus for later-phase trials that have led to the recent approval of olaparib for use in DNA repair-defective lethal prostate cancer.
What we offer
1. A dynamic and supportive research environment
2. Access to state-of-the-art facilities and professional development opportunities
3. Collaboration with leading researchers in the field
4. Competitive salary and pension